menu
    • menu
    [{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Interferon-alpha\/beta-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bexmarilimab","moa":"Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Business Finland","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faron Pharmaceuticals \/ Business Finland","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Business Finland"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Clevegen","moa":"Clever-1-positive TAMs","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FINLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Interferon-alpha\/beta-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"FINLAND","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Interferon Beta-1A","moa":"CD73","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Faron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Faron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Azacitidine","moa":"||Clever-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Faron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Faron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Faron Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Faron Pharmaceuticals

    Menu

    Faron Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Faron Posts Positive Phase II Results in High-Risk Myelodysplastic Syndrome

                            Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastase, being investigated in R/R HR-MDS, in combination with azacitidine.

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Faron Announces Positive Phase II Results in Higher-risk Myelodysplastic Syndrome

                            Details : FP-1305 (bexmarilimab), which inhibits the scavenger receptor Clever-1, is being investigated in combination with azacitidine for relapsed/refractory (r/r) HR MDS.

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : Bexmarilimab,Azacitidine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Faron Doses First HMA-failed MDS Patient with Bexmarilimab in BEXMAB Trial

                            Details : FP-1305 (bexmarilimab), a CLEVER-1 binder, is in Phase 1/2 trials with azacitidine and venetoclax for treating acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia.

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 01, 2024

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Data from Phase 1 BEXMAB Study in Higher-Risk MDS and r/r AML

                            Details : FP-1305 (bexmarilimab) is a first-in-class, humanized mAb that binds to Clever-1, an immunosuppressive receptor on macrophages, being evaluated for high-risk myelodysplastic syndrome.

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 18, 2024

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BEXMAB Data Analysis Provides Insights into HMA-Failed MDS Patient Profiles

                            Details : FP-1305 (bexmarilimab) is a monoclonal antibody binding to Clever-1, currently in phase 1/2 for treating acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia.

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 25, 2024

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory...

                            Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 10, 2023

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia

                            Details : U.S. FDA has granted Orphan Drug Designation to Faron Pharmaceuticals' wholly owned asset bexmarilimab, for the treatment of acute myeloid leukemia. ODD will further help bexmarilimab program by offering clinical development and commercialization benefit...

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 29, 2023

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML a...

                            Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system).

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 19, 2023

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS

                            Details : FP-1305 (bexmarilimab) binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases, which is investigated for the treatment of relapsed/refractory AML and HMA-refractory MmDS patients.

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 11, 2023

                            Lead Product(s) : Bexmarilimab,Azacitidine,Venetoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Faron Pharmaceuticals

                            Finland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexmarilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Faron Announces Upcoming Presentation of Biomarker Analysis from Patients in MATINS Trial at AACR Annual Meeti...

                            Details : The conclusion from analysis is that, when used together, IFNy and TNFa are highly predictive of response to bexmarilimab (P < 0.0001), and patients with low IFNy and TNFa levels experienced significantly higher clinical benefit following treatment with ...

                            Product Name : FP-1305

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 03, 2022

                            Lead Product(s) : Bexmarilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth